History

XINGIMAGING was founded in 2018 by Drs. Tamagnan, Chan, Marek and Seibyl, to

create a unique clinical research company in Asia that combines excellence in clinical

neurology/neuropsychiatry with state-of-art imaging using custom radiopharmaceuticals for

diagnosis and monitoring of neurodegenerative and neuropsychiatric disorders. This fusion of

internationally-recognized expertise in the clinical and imaging arenas into a unified research dedicated organization allows XingImaging to efficiently develop and execute clinical trials for

diagnosis, progression and disease monitoring trials that emphasize quantitative imaging

outcome measures.

XingImaging LLC is a clinical PET imaging service company which offers end to end support of radiopharmaceutical imaging trials. XingImaging’s services include radioligand development, radioligand production, design and implementation of clinical imaging trials utilizing PET, and customized clinical imaging center coordination and management in multicenter imaging studies. 

XingImaging has two related business areas of expertise– Translational Research -development and application of radioligands for both early drug development and/or to investigate disease pathobiology and clinical multi-center imaging Core Lab services to apply radioligands in multi-center studies for subject eligibility and/or disease monitoring.

XingImaging has developed a highly efficient and focused translational research model for

radioligand evaluation enabling us to rapidly and efficiently screen candidate radioligands

moving promising radioligands from chemistry to pre-clinical and human proof of concept

(POC) studies so that these radioligands may be applied to drug development or clinical

questions. XingImaging has the expertise to offer radiochemistry support as needed both for its

translational research studies and to ensure the quality of radiochemistry production and

distribution in multi-center studies. XingImaging also provides comprehensive,

coordinated, clinical research strategies for the application of imaging tracers in multi-center

clinical trials.